Showing results (141-150 of 589) with videos related to
Sort By:
Pageof 59
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 24, 2023
Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor HepatitisMike Wang, Kerry L Reynolds, Kamaneh Montazeri, et al.Oncoimmunology|July 29, 2016
Melanoma driver mutations and immune therapyDouglas B Johnson, Christine M Lovly, Ryan J Sullivan, et al.Oncotarget|October 27, 2015
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanomaNeel M Fofaria, Dennie T Frederick, Ryan J Sullivan, et al.The Journal of Investigative Dermatology|March 11, 2011
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control studyClara Curiel-Lewandrowski, Tamar Nijsten, Maria L Gomez, et al.International Journal of Radiation Oncology, Biology, Physics|May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.Archives of Internal Medicine|September 14, 2011
Prospective evaluation of analgesic use and risk of renal cell cancerEunyoung Cho, Gary Curhan, Susan E Hankinson, et al.Journal for Immunotherapy of Cancer|December 14, 2020
Strategies for improving the management of immune-related adverse eventsAung Naing, Joud Hajjar, James L Gulley, et al.BMC Cancer|October 19, 2017
Societal preferences for adjuvant melanoma health states: UK and AustraliaMark R Middleton, Michael B Atkins, Kaitlan Amos, et al.American Journal of Clinical Dermatology|December 5, 2024
Overcoming Resistance Mechanisms to Melanoma ImmunotherapyDavid X Zheng, David J Bozym, Giuseppe Tarantino, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Exploiting regulatory T-cell populations for the immunotherapy of cancerHans J J van der Vliet, Henry B Koon, Michael B Atkins, et al.Pageof 59